Diffusion Pharmaceuticals Inc. DFFN
We take great care to ensure that the data presented and summarized in this overview for Diffusion Pharmaceuticals Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in DFFN
Top Purchases
Top Sells
About DFFN
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
Insider Transactions at DFFN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 18
2025
|
William Robert Elder CFO, GC & Secretary |
BUY
Open market or private purchase
|
Direct |
2,500
+16.67%
|
$20,000
$8.32 P/Share
|
|
Nov 18
2025
|
Matthew Winton Chief Commercial and Business |
BUY
Open market or private purchase
|
Direct |
1,500
+9.09%
|
$10,500
$7.95 P/Share
|
|
Nov 17
2025
|
John J Alam CEO & President |
BUY
Open market or private purchase
|
Indirect |
10,793
+46.34%
|
$86,344
$8.46 P/Share
|
|
Nov 17
2025
|
John J Alam CEO & President |
BUY
Open market or private purchase
|
Direct |
10,807
+0.72%
|
$86,456
$8.46 P/Share
|
|
Nov 17
2025
|
William Robert Elder CFO, GC & Secretary |
BUY
Open market or private purchase
|
Direct |
1,000
+9.09%
|
$8,000
$8.45 P/Share
|
|
Nov 17
2025
|
Sylvie Gregoire Director |
BUY
Open market or private purchase
|
Indirect |
10,807
+46.37%
|
$86,456
$8.46 P/Share
|
|
Nov 17
2025
|
Sylvie Gregoire Director |
BUY
Open market or private purchase
|
Direct |
10,793
+0.72%
|
$86,344
$8.46 P/Share
|
|
Nov 17
2025
|
Matthew Winton Chief Commercial and Business |
BUY
Open market or private purchase
|
Direct |
3,500
+20.59%
|
$28,000
$8.43 P/Share
|
|
Nov 14
2025
|
Matthew Winton Chief Commercial and Business |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$70,000
$7.57 P/Share
|
|
Nov 14
2025
|
John J Alam CEO & President |
BUY
Open market or private purchase
|
Indirect |
1,707
+50.0%
|
$11,949
$7.57 P/Share
|
|
Nov 14
2025
|
John J Alam CEO & President |
BUY
Open market or private purchase
|
Direct |
1,693
+0.11%
|
$11,851
$7.55 P/Share
|
|
Nov 14
2025
|
Sylvie Gregoire Director |
BUY
Open market or private purchase
|
Indirect |
1,693
+50.0%
|
$11,851
$7.55 P/Share
|
|
Nov 14
2025
|
Sylvie Gregoire Director |
BUY
Open market or private purchase
|
Direct |
1,707
+0.12%
|
$11,949
$7.57 P/Share
|
|
Nov 13
2025
|
John J Alam CEO & President |
BUY
Open market or private purchase
|
Direct |
4,447
+0.3%
|
$31,129
$7.51 P/Share
|
|
Nov 13
2025
|
Sylvie Gregoire Director |
BUY
Open market or private purchase
|
Direct |
4,447
+0.3%
|
$31,129
$7.51 P/Share
|
|
Nov 12
2025
|
John J Alam CEO & President |
BUY
Open market or private purchase
|
Direct |
5,553
+0.38%
|
$38,871
$7.35 P/Share
|
|
Nov 12
2025
|
William Robert Elder CFO, GC & Secretary |
BUY
Open market or private purchase
|
Direct |
3,500
+28.0%
|
$24,500
$7.44 P/Share
|
|
Nov 12
2025
|
Sylvie Gregoire Director |
BUY
Open market or private purchase
|
Direct |
5,553
+0.38%
|
$38,871
$7.35 P/Share
|
|
May 14
2025
|
William Robert Elder CFO, GC & Secretary |
BUY
Open market or private purchase
|
Direct |
4,233
+43.49%
|
$33,864
$8.46 P/Share
|
|
Aug 27
2024
|
William Robert Elder CFO, GC & Secretary |
BUY
Open market or private purchase
|
Direct |
1,000
+44.11%
|
$18,000
$18.16 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 96.2K shares |
|---|